Syncona Ltd.

Syncona Ltd. is a prominent closed-ended investment company with a focus on life sciences. Its primary function is to build and invest in leading life sciences businesses, aiming to accelerate medical advancement and ultimately deliver transformative treatments to patients. Syncona Ltd. strategically emphasizes the creation and development of companies that are at the forefront of scientific innovation, particularly within the fields of gene therapy, cell therapy, and therapeutic biologics. Operating primarily in the biotechnology and healthcare sectors, Syncona targets translational science through substantial equity investments in companies pursuing robust clinical and commercial strategies. Founded by the Wellcome Trust, Syncona has established itself as a significant player in the healthcare investment arena due to its unique approach of leveraging deep scientific and industry expertise to create a portfolio balanced between early and late-stage investments. Its impact on the market is considerable, influencing the integration and application of breakthrough treatments while also aiming to provide strong returns for its shareholders in a socially responsible manner. Through its investments, Syncona contributes to the advancement of medical sciences, addressing significant unmet medical needs worldwide.